

Reshaping the Treatment Landscape in the Department of Veteran Affairs: Immunotherapy in Nonmelanoma Skin Cancer

Resource	Address
Alam M, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. <i>J Am Acad Dermatol</i> . 2018;78:560-578.	https://pubmed.ncbi.nlm.nih.gov/29331386/
Boutros A, Cecchi F, Tanda ET, et al. Immunotherapy for the treatment of cutaneous squamous cell carcinoma. <i>Front Oncol</i> . 2021;11:733917.	https://pubmed.ncbi.nlm.nih.gov/34513710/
Carballo GB, Honorato JR, Farias de Lopes GPF, Spohr TCLSE. A highlight on Sonic hedgehog pathway. <i>Cell Commun Signal</i> . 2018;16:11.	https://pubmed.ncbi.nlm.nih.gov/29558958/
Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. <i>Genome Med</i> . 2017;9:34.	https://pubmed.ncbi.nlm.nih.gov/28420421/
Chang ALS, Tran DS, Cannon JGD, et al. Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study. <i>J Am Acad Dermatol</i> . 2019;80:564-566.	https://www.jaad.org/article/S0190-9622(18)32471-X/pdf
Dummer R, Guminski A, Gutzmer R, et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. <i>Br J Dermatol</i> . 2020;182:1369-1378.	https://pubmed.ncbi.nlm.nih.gov/31545507/
Grob JJ, Gonzalez R, Basset-Seguín N, et al. Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase II trial (KEYNOTE-629). <i>J Clin Oncol</i> . 2020;38:2916-2925.	https://pubmed.ncbi.nlm.nih.gov/32673170/
Gross ND, Miller DM, Khushalani NI, et al. Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. <i>N Engl J Med</i> . 2022;87:1557-1568.	https://pubmed.ncbi.nlm.nih.gov/36094839/
Hughes BGM, Munoz-Couselo E, Mortier L, et al. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): An open-label, nonrandomized, multicenter, phase II trial. <i>Ann Oncol</i> . 2021;32:1276-1285.	https://pubmed.ncbi.nlm.nih.gov/34293460/
Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: Estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. <i>J Am Acad Dermatol</i> . 2013;68:957-966.	https://pubmed.ncbi.nlm.nih.gov/23375456/
Kwan W, Wilson D, Moravan V. Radiotherapy for locally advanced basal cell and squamous cell carcinomas of the skin. <i>Int J Radiat Oncol Biol Phys</i> . 2004;60:406-411.	https://pubmed.ncbi.nlm.nih.gov/15380573/

Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): A multicentre, randomised, double-blind phase 2 trial. <i>Lancet Oncol.</i> 2015;16:716-728.	https://pubmed.ncbi.nlm.nih.gov/25981810/
Migden MR, Khushalani NI, Chang ALS, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: Results from an open-label, phase 2, single-arm trial. <i>Lancet Oncol.</i> 2020;21:294-305.	https://pubmed.ncbi.nlm.nih.gov/31952975/
Morgan FC, Ruiz ES, Karia PS, Besaw RJ, Neel VA, Schmults CD. Brigham and Women's Hospital tumor classification system for basal cell carcinoma identifies patients with risk of metastasis and death. <i>J Am Acad Dermatol.</i> 2021;85:582-587.	https://pubmed.ncbi.nlm.nih.gov/33497751/
Morgan FC, Ruiz ES, Karia PS, Besaw RJ, Neel VA, Schmults CD. Factors predictive of recurrence, metastasis, and death from primary basal cell carcinoma 2 cm or larger in diameter. <i>J Am Acad Dermatol.</i> 2020;83:832-838.	https://pubmed.ncbi.nlm.nih.gov/31600531/
Negbenebor NA. The power of a multidisciplinary tumor board: Managing unresectable and/or high-risk skin cancers. <i>Cutis.</i> 2021;107:E22-E23.	https://pubmed.ncbi.nlm.nih.gov/34288865/
National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology. Basal Cell Skin Cancer. Version 2.2024.	https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf
National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology. Squamous Cell Skin Cancer. Version 1.2024.	https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf
Parikh SA, Patel VA, Ratner D. Advances in the management of cutaneous squamous cell carcinoma. <i>F1000Prime Rep.</i> 2014;6:70.	https://pubmed.ncbi.nlm.nih.gov/25165569/
Rischin D, Migden MR, Lim AM, et al. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: Primary analysis of fixed-dosing, long-term outcome of weight-based dosing. <i>J Immunother Cancer.</i> 2020;8:e000775.	https://pubmed.ncbi.nlm.nih.gov/32554615/
Schmults CD, Karia PS, Carter JB, et al. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: A 10-year, single-institution cohort study. <i>JAMA Dermatol.</i> 2013;149:541-547.	https://pubmed.ncbi.nlm.nih.gov/23677079/
Sekulic A, Migden MR, Basset-Seguín N, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update of the pivotal ERIVANCE BCC study. <i>BMC Cancer.</i> 2017;17:332.	https://bmccancer.biomedcentral.com/articles/10.1186/s12885-017-3286-5
Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. <i>N Eng J Med.</i> 2012;366:2171-2179.	https://www.nejm.org/doi/full/10.1056/nejmoa1113713

Shalhout SZ, Emerick KS, Kaufman HL, Miller DM. Immunotherapy for non-melanoma skin cancer. <i>Curr Oncol Rep.</i> 2021;23:125.	https://pubmed.ncbi.nlm.nih.gov/34448958/
Sharma P, Wagner K, Wolchok J, Allison JP. Novel cancer immunotherapy agents with survival benefit: Recent successes and next steps. <i>Nat Rev Cancer.</i> 2011;11:805-812.	https://pubmed.ncbi.nlm.nih.gov/22020206/
Slater NA, Gooe PB. PD-L1 expression in cutaneous squamous cell carcinoma correlates with risk of metastasis. <i>J Cutan Pathol.</i> 2016;43:663-670.	https://pubmed.ncbi.nlm.nih.gov/27153517/
Stratigos AJ, Sekulic A, Peris K, et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: An open-label, multi-centre, single-arm, phase 2 trial. <i>Lancet Oncol.</i> 2021;22:848-857.	https://pubmed.ncbi.nlm.nih.gov/34000246/
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. <i>CA Cancer J Clin.</i> 2021;71:209-249.	https://pubmed.ncbi.nlm.nih.gov/33538338/
Tejera-Vaquerizo A, Cañueto J, Llombart B, Martorell-Calatayud A, Sanmartín O. Predictive value of sentinel lymph node biopsy in cutaneous squamous cell carcinoma based on the AJCC-8 and Brigham and Women's Hospital staging criteria. <i>Dermatol Surg.</i> 2020;46:857-862.	https://pubmed.ncbi.nlm.nih.gov/31567487/
Venables ZC, Tokez S, Hollestein LM, et al. Validation of four cutaneous squamous cell carcinoma staging systems using nationwide data. <i>Br J Dermatol.</i> 2022;186:835-842.	https://pubmed.ncbi.nlm.nih.gov/34862598/
Verkouteren JAC, Ramdas KHR, Wakkee M, Nijsten T. Epidemiology of basal cell carcinoma: Scholarly review. <i>Br J Dermatol.</i> 2017;177:359-372.	https://pubmed.ncbi.nlm.nih.gov/28220485/
Villani A, Fabbrocini G, Costa C, Scalvenzi M. Sonidegib: Safety and efficacy in treatment of advanced basal cell carcinoma. <i>Dermatol Ther (Heidelb).</i> 2020;10:401-412.	https://pubmed.ncbi.nlm.nih.gov/32297221/
Weinberg AS, Ogle CA, Shim EK. Metastatic cutaneous squamous cell carcinoma: An update. <i>Dermatol Surg.</i> 2007;33:885-899.	https://pubmed.ncbi.nlm.nih.gov/17661931/
Xie P, Lefrançois P. Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis. <i>J Am Acad Dermatol.</i> 2018;79:1089-1100.e17.	https://pubmed.ncbi.nlm.nih.gov/30003981/
Yarchoan M, Albacker LA, Hopkins AC, et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. <i>JCI Insight.</i> 2019;4:e126908.	https://pubmed.ncbi.nlm.nih.gov/30895946/

Resources and Societies

Resource	Address
American Academy of Dermatology Association (AAD). Skin Cancer.	https://www.aad.org/media/stats-skin-cancer
American Cancer Society (ACS). Basal and Squamous Cell Skin Cancer.	https://www.cancer.org/cancer/basal-and-squamous-cell-skin-cancer.html
American College of Mohs Surgery (ACMS)	https://www.mohscollege.org/
American Society of Clinical Oncology (ASCO)	https://www.asco.org/
Centers for Disease Control and Prevention (CDC). What Is Skin Cancer?	https://www.cdc.gov/cancer/skin/basic_info/what-is-skin-cancer.htm
National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology. Basal Cell Skin Cancer. Version 2.2024.	https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1416
National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology. Squamous Cell Skin Cancer. Version 1.2024.	https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1465
Skin Cancer Foundation. Basal Cell Carcinoma Overview.	https://www.skincancer.org/skin-cancer-information/basal-cell-carcinoma/
Skin Cancer Foundation. Squamous Cell Carcinoma Overview.	https://www.skincancer.org/skin-cancer-information/squamous-cell-carcinoma/

All URLs accessed December 5, 2023